4 minute read
Aveeno® releases inaugural State of Skin Sensitivity report
REPORT REVEALS THAT 71% OF ADULTS HAVE SENSITIVE SKIN
The Aveeno® brand launched its first-ever State of Skin Sensitivity Report, which examines the causes of sensitive skin, and explores the connection between body, mind, and skin. While body positivity has spread to mainstream culture in recent years, self-love can be challenging for those of us with sensitive skin. The groundbreaking Aveeno® report shows that 71% of adults identify as having sensitive skin, an astounding increase of 55% in just two decades. The impact of this sensitivity is more than skin deep, as common skin conditions can carry significant psychological impact, influencing quality of life and emotional well-being.
Research from the State of Skin Sensitivity report validates the relationship between emotions and perceptions of sensitive skin.
Skin is both a receiver and a reactor to sensory stimuli, meaning that everything from the environment to skin products can show up in our pores and negatively influence emotions. For example, one-third of patients with skin diseases like acne, atopic dermatitis, psoriasis, and rosacea are estimated to struggle with emotional disorders, including anxiety and depression. Additionally, 50 percent of adults with moderate to severe atopic dermatitis reported that it puts a damper on their social functions, sleep, work productivity, leisure activities, and family relationships.
Aveeno® recognises the broad issue of sensitivity as a skin state, rather than a clinical diagnosis and seeks to shine a light on its prevalence, as well as possible areas of prevention.
‘Treating patients goes well beyond simply analysing their skin. It’s about how their skin impacts their overall emotional well-being, which
is something I consistently see with my patients,’ said Dr. Mara Weinstein Velez, Board Certified Dermatologist and paid Aveeno® consultant. ‘The mind-skin connection is a powerful one, and the Aveeno® brand’s ability to assemble this in-depth report examining the impact of skin sensitivity provides much needed visibility for the dermatology community.’ ‘Our brand heritage is built on leadership and expertise in the sensitive skin state, and this report illustrates the meaningful impact sensitive skin has on people’s lives,’ said KC Hagin, Commercial Leader for Aveeno® at Johnson & Johnson Consumer Inc. ‘We have an obligation not only to provide product solutions but to help de-stigmatise the word ‘sensitive’ and to turn a common struggle into a strength. Aveeno® wants to be front and centre of the conversation and is encouraging everyone to be proud of their sensitive skin.’ To further encourage conversation around what it really means to have Skin is both a receiver sensitive skin, Aveeno® is and a reactor to sensory stimuli, meaning that calling on consumers to share their #ProudlySensitiveSkin everything from the stories on social media. The environment to skin campaign aims to highlight products can show up in our various consumer experiences with skin pores and negatively conditions and showcase influence emotions. how people have learned to love their sensitive skin. By changing the narrative, Aveeno® is facilitating connection with likeminded individuals in a deeper way and celebrating sensitive skin, and all that comes with it. Aveeno® knows that sensitive skin is real and can have a tremendous impact on quality of life which is strongly illustrated in this report. The brand is committed to igniting and fueling the positive narrative around sensitive skin, while also being dedicated to delivering products that bring nourishing solutions to sensitive skin.
BIOLEXA SCORES POSITIVE TRIAL RESULTS
Hoth Therapeutics, Inc., a patient-focused biopharmaceutical company, announced positive data for BioLexa, its investigational therapeutic in a Phase 1b clinical trial in adult patients with mild-to-moderate atopic dermatitis.
Using the SCORAD (SCORing Atopic Dermatitis) as a clinical tool for assessing the severity of atopic dermatitis and EASI score, which is a tool used to measure the extent and severity of atopic eczema all patients showed improvement during the study compared to the day one score. Using the EASI scale, 100% of patients showed clinically-relevant improvement >50% compared to Day 1 during the entire 28 day study treatment period. Using SCORAD 60% of patients showed overall clinically relevant improvement by SCORAD (>35% improvement) during the study compared to the Day 1 score. 42% of patients maintained improvement from day 14 to day 28 (which includes 2 weeks without active treatment). This supports the long-term effect of BioLexa based on the mechanism of action to treat the underlying staphylococcal infection.
A clinically relevant reduction in the total body surface area affected by atopic dermatitis was observed in 71% patients treated with BioLexa; within these patients, the total reduction ranged from 37.5%–71.4%.
BioLexa was well tolerated with no serious adverse events and no drugrelated treatment-emergent adverse events observed, according to the safety results. In addition, >50% of patients reported an improvement in the effect of atopic dermatitis on their quality of life.
Robb Knie, Chief Executive Officer of Hoth Therapeutics, stated, ‘Today’s positive results give us even more confidence that BioLexa can help provide relief from atopic dermatitis in patients, without the harmful long-term effects of corticosteroids and other side effects that many patients suffer with today’s choice of approved therapeutics.’
